• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


Proveris Scientific
Menu
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Ji Xing acquires Chinese rights to two Oyster Point nasal sprays for dry eye

Ji Xing Pharmaceuticals has acquired Chinese development and commercialization rights to Oyster Point Pharma’s OC-01 varenicline nasal spray and OC-02 simpinicline nasal spray for the treatment of dry eye disease in a deal that includes a $17.5 million upfront payment and up to $204.8 million in milestone payments and royalties. Earlier this year, Ji Xing acquired Chinese rights to Milestone Pharmaceutical’s etripamil nasal spray for the treatment of paroxysmal supraventricular tachycardia (PSVT).

Oyster Point’s 505(b)(2) NDA for OC-01 for dry eye disease is currently under review by the FDA, which has set a PDUFA goal date of October 17, 2021 for completion of the review. In June 2021, the company announced that it had initiated a Phase 2 trial of OC-01 for the treatment of neurotrophic keratopathy. In 2018, Oyster Point announced positive results from Phase 2b studies of both OC-01 and OC-02; it has since focused only on OC-01.

Oyster Point CEO Jeffrey Nau commented, “This agreement marks an important step toward providing OC-01 varenicline and OC-02 simpinicline nasal sprays to patients living with dry eye disease globally while strengthening our cash position. We look forward to partnering with the team at Ji Xing to develop and potentially commercialize these novel therapies in the licensed regions.”

Ji Xing CEO Joseph Romanelli said, “Stimulating natural tear film production may be a paradigm-changing way to treat dry eye disease, which affects more than 150 million patients in China. We are excited to partner with the Oyster Point team, who are innovative pioneers focused on developing therapeutics for ophthalmic diseases, and bring both OC-01 and OC-02 to China. OC-01 and OC-02 have the potential to offer a compelling alternative to artificial tears and anti-inflammation eye-drops to help ease the disease burden for patients.”

Read the Oyster Point Pharma and Ji Xing Pharmaceuticals press release.

Share

published on August 9, 2021

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Solstice Air banner
    © 2025 OINDPnews